EGFR and interstitial lung disease: The etiology of ILD associated with EGFR TKI therapy is not fully understood but is thought to be related to inhibition of EGFR and its family members, which are upregulated early in the response to acute lung injury and contribute to the repair of pulmonary damage (Qi et al., 2015).